The role of eosinophils in immunotherapy-related adverse events (IRAES) - immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) and immune effector…

Active Grant Awarded

Award ID
R01CA317772
Recipient
Awarding agency
Obligated
$793,012

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 4% complete
Place of performance
Seattle, WA 98101, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Grant R01CA317772 to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, with $793,012 obligated on September 17, 2026, under the Cancer Treatment Research program (CFDA 93.395). The award funds research on the role of eosinophils in immunotherapy-related adverse events, specifically immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) and immune effector cell-associated neurotoxicity syndrome (ICANS), which are toxicities of CAR-T cell therapy for cancer. Aim 1 tests whether eosinophil depletion reduces toxicity in animal models using genetic and therapeutic approaches, and whether clinical levels of eosinophil degranulation proteins correlate with toxicity onset in a longitudinal human patient cohort. Aim 2 tests whether repurposed FDA-approved drugs that target IL-5, IL-18, and IL-10 reduce IEC-HS and ICANS in established animal models. The program's stated purpose is to develop means to cure as many cancer patients as possible and to control disease in those not cured, through fundamental and applied laboratory and clinical research. The period of performance ends August 31, 2031, and the place of performance is Seattle, WA 98101.

Description

The role of eosinophils in immunotherapy-related adverse events (IRAES) - immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are life-threatening toxicities that impede the widespread adoption of transformative car-T cell therapies for cancer. Occurring in up to 35% of patients, iechs is a strong predictor of poor survival and has led to the premature termination of several clinical trials. The fundamental determinants of these severe immune-related adverse events (SIRAES) remain an unresolved challenge. Our central hypothesis is that SIRAES are the result of a pathological convergence of three factors: an underlying immunological predisposition, the immunological pressures of lymphodepleting chemotherapy, and car-T cell-driven cytokine release, which together lead to an eosinophil-driven tissue pathology that culminates in IEC-HS and ICANS. Preliminary data from our novel mouse models and clinical samples demonstrate that pre-existing elevations of IL-10 and IL-18 correlate with toxicity, and that the accumulation and degranulation of eosinophils in tissues precedes the onset of SIRAES. Furthermore, depletion of eosinophils in our animal models abrogates the development of IEC-HS, supporting a causal role for these cells. We will address this premise with two specific aims. Aim 1 will explore the causal link between eosinophils and IEC-HS by investigating whether eosinophil depletion reduces toxicity in animal models using genetic and therapeutic approaches, and by determining if clinical levels of eosinophil degranulation proteins correlate with toxicity onset in a longitudinal human patient cohort. Aim 2 will test the efficacy of clinical cytokine blockade as a therapeutic strategy to reduce IEC-HS and ICANS by repurposing FDA-approved drugs that target IL-5, IL-18, and IL-10 in our established animal models. The success of this project will unveil a new mechanistic paradigm for car-T cell toxicities. Identifying tissue eosinophilia as a distinct pathological state that precedes SIRAES will provide a strong rationale for early therapeutic interventions, vastly different from current treatment methods, with the potential to prevent toxicity, increase patient survival, and expand the clinical application of car-T therapies. While human patient data validates our cellular markers, current in vitro and computational models cannot sustain viable eosinophil dynamics or reproduce the complex immune crosstalk required to study car-T interactions with the immune system. Therefore, in vivo animal models are required to recapitulate eosinophil biology and enable mechanistic evaluation of car-T-immune interactions that cannot be modeled in existing humanized platforms.

Quick answers

Who received award R01CA317772?

R01CA317772 was awarded to Seattle Children's Hospital by National Cancer Institute (National Institutes of Health) on September 17, 2026.

How much is award R01CA317772 worth?

$793,012 has been obligated on R01CA317772.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award